Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Average Price Target of $15.86

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received an average rating of “Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $15.86.

A number of research analysts have weighed in on the stock. Truist Financial raised their target price on shares of Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Cantor Fitzgerald began coverage on Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating for the company. Guggenheim lifted their price target on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Finally, Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd.

Hedge Funds Weigh In On Inventiva

Several institutional investors and hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP purchased a new position in Inventiva in the first quarter worth approximately $1,111,000. Engineers Gate Manager LP increased its stake in Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after acquiring an additional 43,280 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Inventiva by 78.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock valued at $142,000 after purchasing an additional 17,000 shares during the period. Finally, Platt Investment Counsel LLC purchased a new stake in Inventiva in the third quarter valued at $45,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Trading Up 0.8%

Shares of NASDAQ IVA opened at $3.71 on Monday. The firm has a 50-day simple moving average of $3.86 and a 200-day simple moving average of $4.91. Inventiva has a 52 week low of $2.82 and a 52 week high of $7.29.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $0.75 million for the quarter. Analysts anticipate that Inventiva will post -0.79 EPS for the current fiscal year.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.